KBC Group NV Grows Stock Holdings in Masimo Co. (NASDAQ:MASI)

KBC Group NV lifted its position in Masimo Co. (NASDAQ:MASI - Free Report) by 1,393.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,122 shares of the medical equipment provider's stock after purchasing an additional 17,842 shares during the quarter. KBC Group NV's holdings in Masimo were worth $3,161,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of MASI. Squarepoint Ops LLC acquired a new stake in Masimo during the 2nd quarter valued at approximately $1,220,000. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Masimo by 133.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider's stock worth $44,000 after purchasing an additional 200 shares during the last quarter. SG Americas Securities LLC acquired a new position in Masimo during the third quarter valued at $3,862,000. Handelsbanken Fonder AB boosted its holdings in Masimo by 17.8% in the third quarter. Handelsbanken Fonder AB now owns 13,230 shares of the medical equipment provider's stock valued at $1,764,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Inspire Investing LLC acquired a new stake in Masimo during the 3rd quarter worth about $395,000. Institutional investors and hedge funds own 85.96% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently commented on MASI shares. Piper Sandler upped their target price on Masimo from $180.00 to $210.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 18th. BTIG Research upped their price objective on Masimo from $166.00 to $170.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Raymond James lifted their target price on shares of Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a report on Friday, December 27th. Wells Fargo & Company increased their price target on shares of Masimo from $171.00 to $193.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Finally, Stifel Nicolaus reaffirmed a "buy" rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Masimo currently has a consensus rating of "Moderate Buy" and a consensus target price of $191.40.

Masimo Price Performance

Masimo stock traded up $3.56 during trading on Tuesday, reaching $175.70. The company had a trading volume of 301,640 shares, compared to its average volume of 497,533. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The firm's 50-day simple moving average is $171.24 and its 200 day simple moving average is $145.90. The firm has a market capitalization of $9.41 billion, a PE ratio of 121.17 and a beta of 1.02. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $183.14.

Masimo (NASDAQ:MASI - Get Free Report) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.14. The business had revenue of $504.60 million during the quarter, compared to analysts' expectations of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.63 earnings per share. As a group, equities research analysts anticipate that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.